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Abstract 
Neurexin (NRXN) and Neuroligin (NLGN) are trans-synaptic proteins involved in vascular biology. NRXN 
is encoded in long () and short () isoforms. We have shown that NRXNmodulates blood vessel 
development in synergy with VEGFA and associates with NLGN. On the other hand NRXN is also 
expressed in blood vessels but does not interact with NLGN or act in synergy with VEGFA, thus 
demonstrating a differential role.  
To find clues into the vascular functions of NRXN, we chose a 7 aa motif that is part of its extracellular 
region and was formerly selected through a proteomic search for interactors of the vascular receptor Tie2. 
Next we a) synthetized and modeled such peptide in order to determine its biological activity towards Tie2 in 
in vitro and in vivo angiogenesis assays and b) evaluated if NRXN and Tie2 physically associate in situ 
during vascular development. 
We used biochemical and cellular assays to prove that the synthetic NRXN peptide a) modulates the 
angiogenic phenotype of cultured endothelial cells and angiogenesis in vivo and b) efficiently stimulates 
Tie2 phosphorylation and downstream mediators in endothelial cells. Moreover, we show that NRXN and 
Tie2 can be reciprocally immunoprecipated from chicken blood vessels at late stages of vascular 
development. 
These data have a double significance, i.e. provide a novel tool to modulate Tie2 and further suggest the 
involvement of the NRXN family of synaptic protein in the vascular system through their interaction with a 
fundamental vascular player. 
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1. INTRODUCTION 
Neurexins (NRXNs)1 are a family of pre-synaptic transmembrane proteins involved in the modulation of 
synaptic activity in partnership with the post synaptic Neuroligins (NLGNs). In mammals, there are 3 
different NRXN genes, each presenting 2 alternative promoters which drive the synthesis of 2 major 
isoforms per gene (a long αNRXN, and a short C- terminal βNRXN). The extracellular region of NRXN is 
constituted by three LNS-EGF-LNS repeats while the short βNRXN is made only of the last LNS (6th) 
domain (Figure S1). 
    We recently  discovered that a)  and NRXN as well as NLGN are expressed by blood vessels b) 
NRXN and NLGN modulate angiogenesis in the chick embryo chorioallantoic membrane assay;   c) while 
both NRXN and NRXN co-precipitate with NLGN in brain, only NRXNdoes so in blood vessels [1]d) 
in zebrafish NRXN but not NRXN knock-down causes vascular defect in synergy  with VEGFA [2]. All 
these findings raise questions about NRXN function and protein partners in the vascular system.  In a 
parallel project we screened a phage-displayed random peptide library on the vascular specific receptor Tie2 
in order to find either new small modulators of its activity or discover new physiological partners that could 
participate in the regulation of the complex family of Angiopoietin/Ties. Among the candidate Tie2 ligands 
there was a peptide corresponding to a portion of NRXN. This report analyzes the possibility that Tie2 is 
linked to the vascular NRXN and demonstrates that a) a cyclic peptide that mimics a region of the second 
EGF like domain of NRXN has angiogenesis-promoting activities and specifically displays agonistic 
activity towards Tie2 and its downstream signaling and b) that Tie-2 and NRXN co-precipitate from blood 
vessels in a developmentally regulated fashion. 
 
 
2.  Methods  
 
2.1 Synthesis and validation of Peptides 
Peptide A2 (GTGYLGR) and its cyclic form BbcA2 as well as the control peptide (ADSILRS) were 
synthetized by New England Peptide (Gardner, MA,  USA). The binding of A2 and BbcA2 to Tie2 was 
verified through ELISA on recombinant Tie2 or by immunofluorescence /FACS on Tie2 overexpressing 
cells using FITC-conjugated  peptides.  The control peptide did not bind to Tie-2 in any of these assays (data 
not shown). 
2.2 Proliferation assay 
96 well plates were coated with 1% gelatin in PBS. HUVEC cells, pre-incubated for  24 hours with 15 µM 
peptides or control medium, were seeded in the presence or absence of peptides.  After 24 or 48  hours cells 
were fixed and  colored with crystal violet. Absorbance was read at 595 nm with BioAssay Reader HTS 
7000 Perkin Elmer. 
2.3 Apoptosis-TUNEL assay 
HUVEC cells were incubated with 15 µM peptides. TUNEL  assay (In Situ Cell Death Detection Kit; Roche, 
#12-156-792-910) was performed on the slides followed by image analysis using fluorescent microscopy 
(DM IRB; Leica). DAPI  stain (Molecular probes, Invitrogen, Carlsbad, CA) was used to assess total cell 
number. 
2.4 Protein immunoprecipitation from cultured cells and tissues 
Confluent HeLa cells were washed three times with cold PBS containing 1mM Na orthovanadate and lysed 
in lysis buffer (Tris HCl pH 7,5 50mM, NaCl 150mM, SDS 0,1%, 1% TRITON X-100) plus  protease and 
phosphatase inhibitors (50μg/ml pepstatin, 50μg/ml leupeptin, 10μg/ml aprotinin, 1mM PMSF, 100μM 
1) Abbreviations: NRXN (Neurexin); NRXN (Neurexin ); A2: 7 aa peptide from the second 
EGF like domain of alpha Nrxn; BbcA2: backbone cyclic form of A2; Bbc control: control peptide 
in the cyclic form; EC: endothelial cells; LNS domain: laminin A/ neurexin/ sex hormone-binding 
globulin repeats; NLGN: Neuroligin 
 
ZnCl2, 1mM Na orthovanadate, and 10mM NaF) for 30min. After centrifugation (30min at 11,000g), 
supernatant was quantified with the BCA Protein Assay Reagent Kit (Pierce Chemical Co., Rockford, IL). 
 1mg of proteins were pre-cleared by incubation for 90 minutes  with protein A-Sepharose (Amersham 
Biosciences, Piscataway, NJ) and then incubated with rabbit anti-NRXN (1,5μg/mg) or rabbit anti-Tie2 C-20 
(2,5μg/mg) for 1 h. The immune complexes were recovered on protein A-Sepharose for 90 minutes, beads 
were washed four times and detected by immunoblot. Proteins were separated by 8% SDS-PAGE 
electrophoresis gel, transferred to PVDF membrane (Millipore, Billerica, MA), incubated with mouse 
monoclonal anti-NRXN antibody (BD, Franklin Lakes, NJ), or anti-Tie2 C-20 antibody (Sigma-Aldrich, St. 
Louis, MO). Horseradish-peroxidase conjugated secondary antibody (Jackson Immunoresearch, West Grove, 
PA)was used and visualized by ECL system (Amersham Biosciences, Piscataway, NJ). 
Five Chicken Chorioallantoic Membranes were used for each experimental point. Frozen tissues were 
disaggregated and lysed 40min in ice with a lysis buffer previously  set-up (Tris HCl pH 7,5 20mM; aCl 
100mM, NaHC03 20mM, KCl 4mM, MgCl2 2,5mM; 10% glycerol; 1% triton X-100; 1% CHAPS and 
protease and phosphatase inhibitors. After centrifugation (30min at 11,000g), supernatant was quantified. 
5mg of proteins were pre-cleared by incubation for 90 min with protein A-Sepharose (Amersham 
Biosciences, Piscataway, NJ) and then incubated with rabbit anti-NRXN (1,5μg/mg) or rabbit anti-Tie2 C-20 
(2,5μg/mg) overnight. The immune complexes were recovered on protein A-Sepharose for 90 minutes, beads 
were washed four times and detected by immunoblot. Proteins were separated by 4-15% gradient SDS-
PAGE mini-protean TGX(Biorad, Hercules, CA), transferred to PVDF membrane (Millipore, Billerica, MA), 
incubated with mouse monoclonal anti-NRXN antibody (BD, Franklin Lakes, NJ), or with rabbit anti-Tie2 
C-20 antibody (Sigma-Aldrich, St. Louis, MO).  
2.5 Migration assay 
Subconfluent HUVEC were starved overnight in M199 2%FBS and 1%BSA. The assay was done with 
Boyden chamber with a membrane soaked in 1% gelatin. The lower chamber was filled with serum free 
medium+ stimuli ( 10 g/l VEGF or 15 M peptide), while the upper was filled with a HUVEC cells 
suspension (125.000 CELLS/WELL). After 5 hours the chamber was opened and the cells on the  membrane 
were fixed in methanol and colored with Eosin/Hematoxylin.  
2.6 Morphogenesis assay in matrigel 
48 wells microtiter plates  were covered with 150 l of matrigel (Sigma-Aldrich, St. Louis, MO). 13000 
Huvec/well were prepared in M199 10%FBS with or without 15M of peptides. Photographs were taken 
after 5 hours. Total length of network of tubuli was calculated through an analysis performed by WinRHIZO 
program (Regent Instruments). 
2.7 Sprouting assay 
HUVEC cells  suspended at density of 4cells/μl in M199 20% methocel and 200μl for each spheroid was 
seeded into non adhesive round-bottom 96-well plate. After 12h at 37°C (5% CO2, 100% humidity) 
spheroids were harvested, centrifuged (15min at 300g) and resuspended in collagen solution (Roche, 
Indianapolis, IN) with 15  M of peptide. Photographs were taken after 24 hours. Total length of the sprouts 
was calculated through an analysis performed by WinRHIZO program (Regent Instruments). 
2.8 CAM assay 
Fertilized chick embryos were incubated for 3 days at 37°C at 70% humidity. A small hole was made over 
the air sac at the end of the egg and a second hole was made directly over the embryonic blood vessels. After 
7 days, cortisone acetate–treated filter disks (5 mm) were saturated with 5μl of 100 ng/ml Ang1 (R&D 
Systems) and peptides at concentration of 15 μM. After 3 days CAMs were fixed with PBS-4% 
paraformaldehyde for 10min at room temperature, filter disks were excised and pictures were taken with a 
QIcam FAST1394 digital color camera (QImaging) connected to the stereomicroscope (model SZX9; 
Olympus). 
2.9 Analysis of the Tie2 phosphorylation pathway 
HUVEC cells were incubated with M199 10%FCS with 15 μM peptides for one hour. The cells were then 
lysed  with hot Laemli Buffer and after centrifugation the protein were  quantified. 30μg proteins were 
separates by 7,5% SDS-PAGE mini-protean TGX (Biorad, Hercules, CA), transferred to PVDF  membrane 
(Millipore, Billerica, MA), incubated with mouse monoclonal Anti-Phosphotyrosine, 
4G10® Platinum(Millipore, Billerica, MA), with rabbit anti-pAkt (S473)(D9E) antibody, with mouse 
monoclonal p-p44/42 MAPK (T202/Y204)(E10) antibody (both Cells Signalling, Danvers, MA). For total 
protein normalization purposes we  used rabbit anti-Tie2 C-20 antibody (Sigma-Aldrich, St. Louis, MO), 
rabbit anti-Akt (C67E7) and rabbit p44/42 MAPK (both Cells Signalling, Danvers, MA). Horseradish-
peroxidase conjugated secondary antibody (Jackson Immunoresearch, West Grove, PA) was used and 
visualized by ECL system (Amersham Biosciences, Piscataway, NJ). 
 
 
3. RESULTS 
3.1 A NRXN-EGF domain  peptide affects the angiogenic properties of endothelial cells and in vivo 
angiogenesis. 
A phage display screening on Tie2 provided a large set of 7 aa target peptides of which one (A2- NH2-
GTGYPGR-COOH)  was highly homologous to a sequence (NH2-GTGYLGR-COOH) within the second 
EGF-like domain of NRXN (Figure S1A). Analysis of this sequence on the NRXN crystallography (PDB 
3POY [3], PDB 3QCW  [4]) showed that the peptide is exposed on the external surface of the protein where 
it is found in a coiled conformation (Figure S1B). Studies were pursued further with the A2 homologous 
sequence synthesized in a linear (A2) and cyclic (backbone cyclic, named BbcA2) forms and specific assays 
were performed. 
 
3.1.1  In vitro assays for proliferation, apoptosis and migration 
To verify a possible effect of the peptides on proliferation and cell death, EC  were treated with A2 and 
BbcA2 in proliferation and TUNEL assays. Neither had a significant effect even after a 24 hours incubation 
(Figure S2). On the other hand, migration assays with Boyden chamber showed that BBcA2 promotes the 
migration of EC cells compared to all controls (Figure 1A). 
 
3.1.2  In vitro morphogenesis 
As two of the most relevant assays for angiogenic potential, we measured the ability of EC to form networks 
on matrigel or to sprout from collagen spheroids upon A2 and BbcA2 treatment. In the case of network 
formation on matrigel (Figure 1B), as with the migration assay, only BBcA2 induced a statistically 
significant increase in the tube network length. In the case of spheroid sprouting both A2 and BbcA2 induced 
positive responses, with BbcA2 inducing a response similar in extent to Ang1 (Figure 2A). 
 
3.1.3  In vivo angiogenesis 
We finally tested angiogenic activities of the peptides in vivo. We chose the chick chorioallantoic membrane 
(CAM) assay, which is used as an in vivo model both to study physiological angiogenesis and to test pro- and 
anti-angiogenic compounds. The peptides A2 and BbcA2 applied at day 10, induced the formation of 
capillary bifurcations, with BbcA2 being significantly more effective than its linear counterpart A2 (Figure 
2B). Globally, these results indicate that the NRXN EGF II peptide induces angiogenesis and that 
mimicking its natural conformation though cyclization positively influences its biological activities. 
 
3.1.4  BbcA2 induces Tie2 phosphorylation 
As a complement to the phenotypic data shown above we next tested whether A2 could modulate Tie2 signal 
transduction in EC . Ang1 has been demonstrated to induce activation via phosphorylation of pathways 
downstream to Tie2 [5]. To determine the activity of our peptides, they  were incubated with EC  and the 
phosphorylation of Tie2, Akt and Erk was measured. Figure 3 shows that BbcA2 and A2 enhance the 
phosphorylation of Tie-2 and of the downstream mediators AKT and ERK over their respective controls. 
This attests that the effect on EC migration and morphogenesis is complemented by a specific activation of 
Tie2 and of its main downstream mediators.   
 
NRXN  and Tie2 physically associate in vivo and their interaction is modulated during development 
As an extension to the above data, the physical interaction between Tie2 and NRXN was tested. 
Preliminary sets of experiments were dedicated to identifying complexes of these two proteins in 
overexpressing Hela Cells. NRXN was immunoprecipitated and the resulting precipitate was 
immunoblotted with the antibody against Tie2. Figure S3 shows that Neurexin and Tie-2 can indeed be co-
immunoprecipitated in these conditions. 
To evaluate Nrxn-Tie2 interaction in a physiologically significant environment, we used the chicken 
chorioallantoic membrane. Figure 4 shows that at the stage E10 NRXN and Tie2 can be efficiently co-
immunoprecipitated from the CAMs but not from the brain, where the two proteins are also present. . To 
evaluate a possible modulation of the interaction between NRXN and Tie2 during vascular development, 
we performed co-immunoprecipitation experiments using CAMs at days 5, 10 or 15 days. Interestingly, even 
though the two proteins are expressed at significant levels at all stages, they interact only from day 10 
onward and with increasing intensity (Figure 4B), when blood vessels are mature and well structured. 
 
4. DISCUSSION  
Prior to this report, we discovered that the synaptic protein NRXN  was expressed in the vascular system, 
but unlike the related NRXN and NLGN, does not interact  with VEGFA.  Here,  starting from  the data 
collected  through a parallel project,  the  NRXN link to another pivotal family of vascular mediators, the 
Ang/Tie,  was considered.  
The data describe above data have two implications: 
First, they provide the basis for the construction of a novel targeting tools for Tie2 starting from BbcA2 as 
lead compound. This receptor and its ligands are involved in disparate activities and its pharmacological 
modulation may have an impact in wide array of clinical settings, ranging from angiogenesis to inflammation 
to cancer [6] . BbcA2 is a small peptide activator of the Tie2. Although other instances of peptide activators 
of signaling pathways are known, in the case of Tie2, another 7aa ligand has been identified with inhibitory 
effects [7]. One hypothesis is that the latter peptide may function by inhibiting Tie2 dimerization [8]  while 
BbcA2 could relieve the receptor from some inhibitory interactions, of which the most plausible is the one 
with the strictly related, orphan receptor Tie1[9], or that with NRXN, shown above. The idea that the 
interaction between Tie2 and NRXN is inhibitory (i.e. antiangiogenic) is supported by the fact that they 
associate only when blood vessels are mature and stabilized. Indeed, the CAM is a well characterized 
developmental model in which different stages of vascular remodeling, including endothelial “coverage” by 
developing smooth muscle cells, have been recognized at late stages of development [10]. In addition,  it is 
well known that Ang1 and Tie2 null mice display defects in the maturation and maintenance of the integrity 
of blood vessels [11]. 
Second, our data emphasize the involvement of NRXNs in the vascular system by linking them to a key 
family of vascular modulators such as the Ang/Tie system. In particular, along with our previous data, they 
suggest that Tie2 may be a ligand for NRXN alternative to NLGN, and that NRXN and βNRXN may 
have differential activities in blood vessels, i.e. pro-angiogenic for βNRXN and vessel stabilizing for 
NRXN. 
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LEGEND TO THE FIGURES 
 
 Fig.1: BbcA2 induces migration and tube formation of HUVEC cells. 
 
A) Boyden chamber assay shows that only BbcA2 (15 uM) displays a statistically significant effect on 
migration.  
The graph displays the number of migrated cells from 3 different experiments (n=9 for each experimental 
point). 
Data are expressed as mean ±SEM. ANOVA gave F= 8.771 .** P < 0.01 for BbcA2 vs Bbc Control by 
Bonferroni posttest. 
B) Upper panel: tube morphogenesis assay: representative images showing tube formation on matrigel 5 
hours after plating. Lower panel: quantification of total tube length from 3 different experiments (n=9 for 
each experimental point). Data are expressed as mean ±SEM. ANOVA gave F= 30.88 .** P < 0.01 for 
BbcA2 vs Bbc Control by Bonferroni postTest 
Control: linear control peptide; Bbc control: Backbone cyclic control peptide 
 
 
Fig. 2: A2 and BbcA2 induce  HUVEC sprouting  and in vivo angiogenesis. 
 
A) Sprouting assays. Upper panel : representative images of collagen sprouting upon different treatments. 
Lower panel: quantification of total sprout length  from 4 different experiments (n=15 for each 
experimental point). Data are expressed as mean  ±SEM. ANOVA gave F= 14.53 .*** P < 0.001 for 
BbcA2 vs Bbc Control ** P < 0.01 for A2 vs Control  by Bonferroni posttest. 
B) CAM angiogenesis assay: upper panel: representative images of CAMs upon different 
treatments. Lower panel: quantification graph from 5 different experrints. (n=25 per each 
experimental point). Bars represent the number of vessel bifurcations per disc counted 
after the different treatments Data are expressed as mean  ±SEM. ANOVA gave F= 45.73 
.** * P < 0.001 for BbcA2 vs Bbc ** P < 0.01 for A2 vs Control  by Bonferroni 
posttest. 
Control: linear control peptide; Bbc control: Backbone cyclic control peptide 
 
 
Fig 3: A2 and BbcA2 induce the the activation of the Tie2 downstream pathway. 
 
A) HUVEC cells were incubated with the different peptides for 1 hour and the phosphorylation 
status of Tie2, AKT and ERK was revealed by western blot. 
B) Quantification analysis: bars represent the ratio between the intensity of the 
phosphorylated / total protein bands as quantified by image analysis. 
Data are expressed as mean ±SEM from four different experiments  
Control: linear control peptide; Bbc control: Backbone cyclic control peptide 
 
 
 
Fig 4: Tie2 and alpha Nrxn can be reciprocally immunoprecipitated  from the chicken Cam. 
 
A) Reciprocal immunoprecipitation of Tie 2 and aNrxn from chicken CAMs. 
Tie2 or Nrxn were immunoprecipitated from E10 chicken embryo CAMs or brain and the precipitates were 
blotted for the respective partner. Nrx and Tie2 are espressed by both CAMs and brain, but are co-
immunoprecipitated with high efficiency only from the CAMs. 
B) Developmental modulation of the Tie2/alphaNrxn interaction.Co-immunoprecipitation experiments 
performed as in panel A on CAMs at 5, 10 or 15 days of development show that the Tie2/alpha Nrxn 
interaction occurs only at day 10 and 15 when blood vessels are mature and well structured.   
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FigS1: 
 A ) schematic representation  of the Neurexins (alpha and beta ) and Neuroligins arrangements and  structures at the synapse 
 and the position of the  A2 peptide. 
   
B) Display of the three dimensional position of the A2 peptide (sequence : GTGYLGR) on the second EGF 
 domain  of aNRXN  (modeled on PDB  3POY with the  Pymol software, The PyMOL Molecular Graphics System,  Schrödinger, LLC.) . 
 Green : EGF domain, red: A2 peptide. 
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Fig S2: Assays for proliferation and apoptosis of HUVEC cells upon A2 and BBCA2 treatment. 
A) treated or untreated HUVEC cells (15µM for  36 hours)   were xed  and stained  with crystal violet.  
Proliferation was evaluated by absorbance reading  at 595 nm.
B) HUVEC cells were treated as above and apoptosis was measured by a  TUNEL assay. 
Quantication of apoptotic cells   was manually performed using uorescence  microscopy  
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Fig S3: in vitro  co-immunprecipitation of Tie2 and alphaNRXN.  
 alphaNRXN  was immunoprecipated from Hela cells  overexpressing 
alphaNRXN and Tie2 and the resulting precipitate was blotted against 
Tie2 (upper gel) or Nrxn (lower gel). 
Lysate obtained from  E18 Chick embryo brain was used as a positive 
control for Neurexin blotting while  lysate from Tie2 overexpressing 
porcine aortic  endothelial cells was used as a positive control for Tie2 blotting. 
